8-K: Datavault AI Secures $10M Upfront in Biotech Data License

Datavault AI Inc. grants Scilex Holding Company an exclusive worldwide license for its AI-driven data tokenization technology in biotech, securing a $10 million upfront fee and up to $2.55 billion in sales milestones.

Summary

• Datavault AI Inc. (DVLT) entered into a worldwide, exclusive, non-transferable license agreement with Scilex Holding Company (SCLX) on November 3, 2025.
• The agreement grants Scilex the right to research, develop, use, sell, and commercialize Datavault AI's proprietary materials, including patents and know-how related to its data platforms, within the biotechnology, biopharmaceutical, genetic, diagnostic, and data-related industries (Target Market).
• Scilex will leverage Datavault AI's AI-driven technology to create and operate a Biotech Exchange platform for secure tokenization, trading, and monetization of biotech assets like genomic and DNA data, diagnostic and therapeutic products, genetic information, and drug data.
• As consideration, Datavault AI will receive a non-refundable license fee of $10,000,000, payable in four equal installments of $2,500,000, with the first due by December 31, 2025, and subsequent payments by March 31, 2026, June 30, 2026, and September 30, 2026.
• Datavault AI is also eligible for sales milestone payments up to an aggregate of $2,550,000,000 upon Scilex achieving certain net sales for the licensed product.
• Additionally, Datavault AI will receive a five-percent (5%) royalty on net sales of the product during the applicable royalty term.
• The license agreement is subject to earlier termination if Scilex fails to make required payments within 15 days or does not achieve and maintain annual royalty payments of a minimum of $1,000,000 after 24 months from the agreement date.
• The agreement highlights Datavault AI's robust intellectual property portfolio, including patents for 'Platform and Method for Tokenizing DNA Data' and other data management and tokenization systems.

Sentiment

Score: 9

Explanation: The filing indicates a highly positive development for Datavault AI, securing a substantial upfront payment, significant potential milestone payments, and a recurring royalty stream. It validates the company's core technology and opens access to a massive estimated market opportunity, suggesting strong future revenue potential and strategic positioning.

Positives

• Secured a significant non-refundable upfront license fee of $10,000,000, providing immediate revenue.
• Potential for substantial future revenue through sales milestone payments, up to an aggregate of $2,550,000,000.
• Establishment of a recurring revenue stream with a 5% royalty on net sales of products developed by Scilex.
• Validation of Datavault AI's intellectual property and AI-driven blockchain technology through a major licensing deal with a publicly traded company.
• Entry into the large and growing biotechnology and pharmaceutical data market, estimated at $2.0 trillion for tokenization opportunities.
• The agreement provides a mechanism for non-dilutive funding for companies utilizing the platform, potentially increasing adoption and market reach.

Risks

• General economic, political, and business conditions could impact the success of the agreement.
• The ability to achieve the anticipated benefits of the license agreement and other contemplated transactions with Scilex is not guaranteed.
• Potential for legal proceedings related to the transactions contemplated with Scilex, including the license agreement.
• The transactions contemplated with Scilex could disrupt current plans and operations.
• Uncertainty regarding the ability to develop and successfully market technologies.
• Challenges in growing and managing growth profitably and retaining key employees.
• Risk that potential technologies may not progress or receive required approvals within expected timelines or at all.
• Uncertainty regarding regulatory pathways for biotech data tokenization and exchange.
• Risk of overestimating the size of the target market, willingness to adopt new technologies, or success of partnerships.
• Prior results and collaborations may not be replicated in this new venture.
• Regulatory and intellectual property risks inherent in the biotech and data tokenization industries.
• Risk of failure to realize the anticipated benefits of the transactions contemplated with Scilex.
• Risk that Datavault AI will not benefit from a Pharmaceutical Exchange platform as envisioned.

Future Outlook

Datavault AI believes its technology has the potential to extend into a Pharmaceutical Exchange platform, which could transform the pharmaceutical industry by enabling efficient, secure asset management and monetization. The company estimates an opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales. Tokenization on such exchange platforms is also seen as an alternative for companies to secure non-dilutive funding for developing and commercializing diagnostic and therapeutic products.

Management Comments

• Datavault AI believes this technology has the potential to extend into a Pharmaceutical Exchange platform, which could transform the pharmaceutical industry by enabling efficient, secure asset management and monetization.
• Datavault AI estimates an opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales.

Industry Context

This licensing agreement positions Datavault AI at the forefront of the rapidly evolving digital health and biotech industries, where the secure management, tokenization, and monetization of sensitive data (like genomic and DNA data) are becoming increasingly critical. By partnering with Scilex, a company focused on non-opioid pain management and neurodegenerative/cardiometabolic diseases, Datavault AI is extending its AI-driven blockchain solutions into a specialized and high-value segment of the healthcare market. This aligns with broader industry trends towards leveraging advanced data analytics, AI, and blockchain for intellectual property management, asset commercialization, and non-dilutive financing within life sciences.

Stakeholder Impact

• Shareholders: Highly positive impact due to significant potential revenue streams (upfront fee, milestones, royalties) and validation of intellectual property, which could lead to increased share price.
• Employees: Potential for growth and expansion within Datavault AI as the company supports Scilex and explores further market opportunities.
• Customers (Scilex's end-users): Will benefit from the development of a secure and efficient Biotech Exchange platform for data tokenization and monetization.
• Creditors: Improved financial health and revenue outlook for Datavault AI could enhance creditworthiness.

Next Steps

• Scilex to make the first $2,500,000 license fee installment by December 31, 2025, followed by three more quarterly installments.
• Scilex to develop and commercialize products using Datavault AI's proprietary materials within the Target Market.
• Datavault AI to provide technology transfer and ongoing cooperation to Scilex.
• Scilex to achieve and maintain a minimum of $1,000,000 in annual royalty payments after 24 months to avoid potential termination.

Key Dates

Recommendation

The licensing agreement with Scilex represents a significant validation of Datavault AI's core technology and intellectual property. The deal includes a substantial $10 million upfront payment, potential milestone payments up to $2.55 billion, and a 5% royalty on net sales, providing multiple avenues for significant revenue generation. This non-dilutive funding mechanism, coupled with access to an estimated $2.0 trillion market opportunity in biotech and pharmaceutical data tokenization, positions Datavault AI for substantial long-term growth. The agreement de-risks future development and provides a clear path to monetization in a high-growth sector, making it a strong buy for investors seeking exposure to AI-driven blockchain solutions in healthcare.

Keywords

AI, blockchain, data monetization, asset tokenization, biotech, biopharmaceutical, genomic data, DNA data, diagnostics, therapeutics, genetic information, drug data, licensing agreement, intellectual property, Scilex Holding Company, Datavault AI Inc.